Search results
Showing 801 to 850 of 2065 results for work
This quality standard covers diagnosing and managing multiple sclerosis (MS) in adults. It includes care, support and review for people with MS. It describes high-quality care in priority areas for improvement.
View quality statements for QS108Show all sections
Risankizumab for previously treated moderately to severely active Crohn's disease (TA888)
Evidence-based recommendations on risankizumab (Skyrizi) for previously treated moderately to severely active Crohn's disease in people 16 years and over.
This guideline covers diagnosing and managing Lyme disease. It aims to raise awareness of when Lyme disease should be suspected and ensure that people have prompt and consistent diagnosis and treatment. It does not cover preventing Lyme disease.
Osimertinib for treating EGFR T790M mutation-positive advanced non-small-cell lung cancer (TA653)
Evidence-based recommendations on osimertinib (Tagrisso) for treating epidermal growth factor receptor (EGFR) T790M mutation-positive locally advanced or metastatic non-small-cell lung cancer (NSCLC) in adults.
Ozanimod for treating moderately to severely active ulcerative colitis (TA828)
Evidence-based recommendations on ozanimod (Zeposia) for treating moderately to severely active ulcerative colitis in adults when conventional or biological treatments cannot be tolerated or are not working well enough.
Ex-situ machine perfusion devices for extracorporeal preservation of lungs for transplant
In development Reference number: GID-HTE10084 Expected publication date: TBC
Testing strategies for Lynch syndrome in people with endometrial cancer (HTG557)
Evidence-based recommendations on testing strategies for Lynch syndrome for people with endometrial cancer.
In development Reference number: GID-TA11278 Expected publication date: TBC
Risankizumab for treating moderately to severely active ulcerative colitis (TA998)
Evidence-based recommendations on risankizumab (Skyrizi) for treating moderately to severely active ulcerative colitis in adults.
NICE has developed a medtech innovation briefing (MIB) on microINR for anticoagulation therapy .
pCONUS2 Bifurcation Aneurysm Implant for complex intracranial aneurysms (MIB222)
NICE has developed a medtech innovation briefing (MIB) on pCONUS2 Bifurcation Aneurysm Implant for complex intracranial aneurysms .
Filgotinib for treating moderate to severe rheumatoid arthritis (TA676)
Evidence-based recommendations on filgotinib (Jyseleca) for moderate to severe rheumatoid arthritis in adults.
The government has today (1 December 2025) announced that it will increase the thresholds NICE uses in evaluations of new medicines to decide which are cost-effective for use in the NHS.
Guadecitabine for untreated acute myeloid leukaemia [ID1411]
Discontinued Reference number: GID-TA10325
This guide outlines the main elements of the interim process and methods for the NICE clinical guideline updates using standing committees pilot programme, including details of the Clinical Guidelines Updates committee, which were agreed by the NICE Board in September 2013
Bevacizumab gamma for treating wet age-related macular degeneration (TA1022)
Evidence-based recommendations on bevacizumab gamma (Lytenava) for treating wet age-related macular degeneration in adults.
Evidence-based recommendations on latanoprost–netarsudil (Roclanda) for previously treated primary open-angle glaucoma or ocular hypertension in adults.
Evidence-based recommendations on dabigatran etexilate (Pradaxa) for preventing stroke and systemic embolism in adults with non-valvular atrial fibrillation.
Pomalidomide for multiple myeloma previously treated with lenalidomide and bortezomib (TA427)
Evidence-based recommendations on pomalidomide (Imnovid) for multiple myeloma previously treated with lenalidomide and bortezomib in adults.
Evidence-based recommendations on on regorafenib (Stivarga) for previously treated gastrointestinal stromal tumours in adults.
Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer (TA509)
Evidence-based recommendations on pertuzumab (Perjeta) for treating HER2-positive, locally recurrent or metastatic (secondary) breast cancer that has not been treated with chemotherapy or targeted HER-2 therapy before, in adults.
Evidence-based recommendations on anakinra (Kineret) for treating adult-onset Still’s disease and systemic juvenile idiopathic arthritis in people 8 months and older.
New sepsis guideline targets faster, tailored treatments to benefit patients
Patients aged 16 or over with suspected sepsis will receive more tailored treatment under updated NICE guidance published today.
YOURmeds for medication support in long-term conditions (MIB289)
NICE has developed a medtech innovation briefing (MIB) on YOURmeds for medication support in long-term conditions .
NICE has developed a medtech innovation briefing (MIB) on 24/7 EEG SubQ for epilepsy .
Child maltreatment: when to suspect maltreatment in under 18s (CG89)
This guideline covers the signs of possible child maltreatment in children and young people aged under 18 years. It aims to raise awareness and help health professionals who are not child protection specialists to identify the features of physical, sexual and emotional abuse, neglect and fabricated or induced illness.
Our system implementation team works with organisations to help to put our guidance into practice. We work with NHS, local authority and other organisations in their area, ensuring regular interaction with our stakeholders.
Discontinued Reference number: GID-TA10937
Durvalumab for treating recurrent or metastatic squamous cell head and neck cancer [ID3752]
Discontinued Reference number: GID-TA10617
Pembrolizumab for previously treated endometrial cancer [ID1205]
Discontinued Reference number: GID-TA10243
Discontinued Reference number: GID-TA10836
Discontinued Reference number: GID-TA10965
Evidence-based recommendations on brolucizumab (Beovu) for diabetic macular oedema in adults.
Pembrolizumab with lenvatinib for untreated advanced melanoma [ID3948]
Discontinued Reference number: GID-TA10848
Discontinued Reference number: GID-TA10875
Discontinued Reference number: GID-TA10768
This quality standard covers assessing and managing motor neurone disease, including care, support and planning after diagnosis. It describes high-quality care in priority areas for improvement.
View quality statements for QS126Show all sections
Sections for QS126
- Quality statements
- Quality statement 1: Information and support at diagnosis
- Quality statement 2: Respiratory assessment and non-invasive ventilation
- Quality statement 3: Provision of equipment and adaptions based on multidisciplinary team assessment
- Quality statement 4: Continuity of care
- Quality statement 5: Planning for end of life care
- About this quality standard
Elosulfase alfa for treating mucopolysaccharidosis type 4A (HST19)
Evidence-based recommendations on elosulfase alfa (Vimizim) for treating mucopolysaccharidosis type 4A in people of all ages.
Vemurafenib for treating resected BRAF V600 mutation-positive melanoma [ID1250]
Discontinued Reference number: GID-TA10213
AT406 for neoadjuvant treatment of epithelial ovarian cancer [ID1428]
Discontinued Reference number: GID-TA10809
NICE has developed a medtech innovation briefing (MIB) on Optowire for measuring fractional flow reserve .
Melanoma (advanced, unresectable, metastatic, NRAS mutation positive) - binimetinib [ID833]
Discontinued Reference number: GID-TA10074
Discontinued Reference number: GID-TAG381
Empagliflozin for type 1 Diabetes Mellitus, adjunct to insulin ID1275
Discontinued Reference number: GID-TA10375
Idasanutlin with cytarabine for treating relapsed or refractory acute myeloid leukaemia [ID1597]
Discontinued Reference number: GID-TA10494
Nivolumab with ipilimumab for neoadjuvant treatment of early non-small-cell lung cancer [ID3756]
Discontinued Reference number: GID-TA10631
Rigosertib for previously treated high-risk myelodysplastic syndrome [ID805]
Discontinued Reference number: GID-TA10709
Venous thromboembolism (recurrent) - idraparinux sodium [ID395]
Discontinued Reference number: GID-TAG384
Rociletinib for previously treated EGFR T790M-positive metastatic non-small-cell lung cancer [ID883]
Discontinued Reference number: GID-TA10045
PEGPH20 with nab-paclitaxel and gemcitabine for treating metastatic pancreatic cancer ID1502
Discontinued Reference number: GID-TA10402